



107 results

1

- 1 **Empirical rescue treatment of *Helicobacter pylori* infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on *H. pylori* management (Hp-EuReg).**  
Burgos-Santamaría D, Nyssen OP, Gasbarrini A, Vaira D, Pérez-Aisa Á, Rodrigo L, Pellicano R, Keco-Huerta A, Pabón-Carrasco M, Castro-Fernandez M, Boltin D, Barrio J, Phull P, Kupcinskas J, Jonaitis L, Ortiz-Polo I, Tepes B, Lucendo AJ, Huguet JM, Areia M, Jurecic NB, Denkovski M, Bujanda L, Ramos-San Román J, Cuadrado-Lavín A, Gomez-Camarero J, Jiménez Moreno MA, Lanas A, Martínez-Dominguez SJ, Alfaro E, Marcos-Pinto R, Milivojevic V, Rokkas T, Leja M, Smith S, Tonkić A, Buzás GM, Doulberis M, Venerito M, Lerang F, Bordin DS, Lamy V, Capelle LG, Marlicz W, Dobru D, Gridnyev O, Puig I, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators.  
*Gut*. 2022 Dec 5;gutjnl-2022-328232. doi: 10.1136/gutjnl-2022-328232. Online ahead of print. PMID: 36591610
- 2 **Potential Impact of *Helicobacter pylori* Infection on Pancreatic Cancer Pathophysiology.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Doulberis M.  
*J Gastrointest Cancer*. 2022 Dec 6. doi: 10.1007/s12029-022-00897-x. Online ahead of print. PMID: 36471196 No abstract available.
- 3 **A potential impact of *Helicobacter pylori*-related metabolic syndrome on early and long-term outcomes of bariatric surgery.**  
Kountouras J, Doulberis M, Polyzos SA, Tziritidou M, Chatzopoulos D, Gialamprinou D, Kotronis G, Vardaka E, Liatsos C, Papaefthymiou A. *Gastrointest Endosc*. 2022 Dec;96(6):1088-1089. doi: 10.1016/j.gie.2022.07.003. PMID: 36404088 No abstract available.
- 4 **Potential impact of *Helicobacter pylori*-related metabolic syndrome on arterial hypertension outcomes.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Kyraillidi F, Doulberis M.  
*Am J Hypertens*. 2022 Oct 22;hpac120. doi: 10.1093/ajh/hpac120. Online ahead of print. PMID: 36272097  
No abstract available.
- 5 **The Role of the Pediatric Yorkhill Malnutrition Score (PYMS), Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Malnutrition Prediction of Hospitalized Children.**  
Gysi S, Doulberis M, Légeret C, Köhler H.  
*Children (Basel)*. 2022 Sep 13;9(9):1378. doi: 10.3390/children9091378. PMID: 36138687  
[Free PMC article.](#)
- 6 **Emerging parameters relevant to the management of antimicrobial-resistant *Helicobacter pylori* infection.**  
Kountouras J, Doulberis M, Polyzos SA, Kazakos E, Vardaka E, Tziritidou-Chatzopoulou M, Chatzopoulos D, Liatsos C, Kyriakopoulos A, Papaefthymiou A. *Intern Med J*. 2022 Sep;52(9):1654-1655. doi: 10.1111/imj.15872. PMID: 36100561 No abstract available.
- 7 **Impact of Active *Helicobacter pylori* Infection-related Metabolic Syndrome on Systemic Arterial Hypertension.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Kazakos E, Vardaka E, Touloumtzi M, Tziritidou-Chatzopoulou M, Liatsos C, Sgantzou IK, Knuchel J, Doulberis M.  
*Arq Bras Cardiol*. 2022 Sep;119(3):502-504. doi: 10.36660/abc.20210931.  
PMID: 36074383 [Free PMC article.](#) English, Portuguese. No abstract available.
- 8 **Potential impact of *Helicobacter pylori* and metabolic syndrome-related non-alcoholic fatty liver disease on cardiocerebrovascular disease.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Liatsos C, Tziritidou-Chatzopoulou M, Chatzopoulos D, Vardaka E, Gialambrinou D, Kotronis G, Doulberis M. *Metabolism*. 2022 Oct;135:155276. doi: 10.1016/j.metabol.2022.155276. Epub 2022 Aug 6. PMID: 35940250 No abstract available.
- 9 **Adverse Outcomes of E-cigarette in Inflammatory Bowel Disease.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Liatsos C, Tziritidou-Chatzopoulou M, Chatzopoulos D, Vardaka E, Gialamprinou D, Kotronis G, Thavayogarahaj T, Doulberis M.  
*Dig Dis Sci*. 2022 Aug 5. doi: 10.1007/s10620-022-07642-1. Online ahead of print. PMID: 35930122 No abstract available.
- 10 **Diagnostic approach to *Helicobacter pylori*-related gastric oncogenesis.**  
Rupp S, Papaefthymiou A, Chatzimichael E, Polyzos SA, Spreitzer S, Doulberis M, Kuntzen T, Kountouras J. *Ann Gastroenterol*. 2022 Jul-Aug;35(4):333-344. doi: 10.20524/aog.2022.0725. Epub 2022 Jun 2.

PMID: 35784633 [Free PMC article](#). Review.

- 11 [Comments on "dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events"](#).  
Kountouras J, Papaefthymiou A, Liatsos C, Tzitiviridou-Chatzopoulou M, Chatzopoulos D, Gialamprinou D, Kotronis G, Vardaka E, Kazakos E, Doulberis M. *Clin Nutr*. 2022 Aug;41(8):1855-1856. doi: 10.1016/j.clnu.2022.06.015. Epub 2022 Jun 24. PMID: 35780067 No abstract available.
- 12 [Helicobacter pylori, gastric microbiota and gastric cancer relationship: Unrolling the tangle.](#)  
Liatsos C, Papaefthymiou A, Kyriakos N, Galanopoulos M, Doulberis M, Giakoumis M, Petridou E, Mavrogiannis C, Rokkas T, Kountouras J. *World J Gastrointest Oncol*. 2022 May 15;14(5):959-972. doi: 10.4251/wjgo.v14.i5.959. PMID: 35646287 [Free PMC article](#). Review.
- 13 [Mortality in Cyprus Over the Period 2016-2021.](#)  
Avraam D, Economidou EC, Kountouras J, Doulberis M, Soteriades ES. *Cureus*. 2022 Apr 20;14(4):e24325. doi: 10.7759/cureus.24325. eCollection 2022 Apr. PMID: 35607558 [Free PMC article](#).
- 14 [Letter to the Editor Regarding "The Association of Helicobacter pylori, Eradication, and Early Complications of Laparoscopic Sleeve Gastrectomy" by Abeid et al.](#)  
Kountouras J, Papaefthymiou A, Polyzos SA, Liatsos C, Vardaka E, Touloumtzi M, Tzitiviridou-Chatzopoulou M, Chatzopoulos D, Doulberis M. *Obes Surg*. 2022 Jun;32(6):2079-2080. doi: 10.1007/s11695-022-06045-5. Epub 2022 Apr 12. PMID: 35412262 No abstract available.
- 15 [ACUTE MYOPERICARDITIS IN A PATIENT WITH ULCERATIVE COLITIS AND THE ROLE OF MESALAMINE: A CASE REPORT.](#)  
Papaefthymiou A, Kyriakos N, Giakoumis M, Doulberis M, Mylonas I, Kountouras J, Liatsos C. *Gastroenterol Nurs*. 2022 Jul-Aug 01;45(4):276-277. doi: 10.1097/SGA.0000000000000617. Epub 2022 Mar 11. PMID: 35283437 No abstract available.
- 16 [GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection.](#)  
Kountouras J, Kazakos E, Polyzos SA, Chatzopoulos D, Tzitiviridou-Chatzopoulou M, Doulberis M, Papaefthymiou A, Vardaka E. *Helicobacter*. 2022 Jun;27(3):e12884. doi: 10.1111/hel.12884. Epub 2022 Mar 7. PMID: 35257445 No abstract available.
- 17 [Global multi-stakeholder endorsement of the MAFLD definition.](#)  
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. *Lancet Gastroenterol Hepatol*. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. PMID: 35248211 No abstract available.
- 18 [Ofelein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and NonPharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.](#)  
Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiviridou-Chatzopoulou M, Papazoglou DD, Doulberis M. *Medicina (Kaunas)*. 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309. PMID: 35208631 [Free PMC article](#). Review.
- 19 [High-flow versus conventional nasal cannula oxygen supplementation therapy and risk of hypoxia in gastrointestinal endoscopies: a systematic review and meta-analysis.](#)  
Doulberis M, Sampsonas F, Papaefthymiou A, Karamouzos V, Lagadinou M, Karampitsakos T, Stratakos G, Kuntzen T, Tzouveleakis A. *Expert Rev Respir Med*. 2022 Mar;16(3):323-332. doi: 10.1080/17476348.2022.2042256. Epub 2022 Feb 22. PMID: 35157538
- 20 [Correspondence on 'Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis' by Rizos et al.](#)  
Kountouras J, Doulberis M, Kazakos E, Tzika SK, Vardaka E, Liatsos C, Papaefthymiou A. *Heart*. 2022 Apr;108(8):657. doi: 10.1136/heartjnl-2020-318776. Epub 2022 Feb 9. PMID: 35140109 No abstract available.
- 21 [Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents.](#)  
Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. *J Crohns Colitis*. 2022 Jun 24;16(5):852-862. doi: 10.1093/ecco-jcc/jjab212. PMID: 34972203

- 22 **Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (HpEuReg).**  
Nysen OP, Vaira D, Pérez Aísa Á, Rodrigo L, Castro-Fernandez M, Jonaitis L, Tepes B, Vologzhanina L, Caldas M, Lanas A, Lucendo AJ, Bujanda L, Ortuño J, Barrio J, Huguet JM, Voynovan I, Lasala JP, Sarsenbaeva AS, Fernandez-Salazar L, Molina-Infante J, Jurecic NB, Areia M, Gasbarrini A, Kupčinskas J, Bordin D, Marcos-Pinto R, Lerang F, Leja M, Buzas GM, Niv Y, Rokkas T, Phull P, Smith S, Shvets O, Venerito M, Milivojevic V, Simsek I, Lamy V, Bytzer P, Boyanova L, Kunovský L, Beglinger C, Doulberis M, Marlicz W, Goldis A, Tončić A, Capelle L, Puig I, Megraud F, Morain CO, Gisbert JP; European Registry on Helicobacter pylori Management Hp-EuReg Investigators.  
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2243-2257. doi: 10.1016/j.cgh.2021.12.025. Epub 2021 Dec 23. PMID: 34954341
- 23 **Impact of Helicobacter pylori-related metabolic syndrome with hyperhomocysteinemia on extragastric pathologies.**  
Kountouras J, Doulberis M, Polyzos SA, Kazakos E, Vardaka E, Touloumtzi M, Manolakis A, Tzitivridou-Chatzopoulou M, Liatsos C, Sotiriades ES, Ntona S, Papaefthymiou A.  
J Gastroenterol Hepatol. 2022 Feb;37(2):407-408. doi: 10.1111/jgh.15753. Epub 2021 Dec 15.  
PMID: 34894006 No abstract available.
- 24 **Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Deretzi G, Vardaka E, Soteriades ES, Tzitivridou-Chatzopoulou M, Gkolfakis P, Karafyllidou K, Doulberis M. Microorganisms. 2021 Nov 14;9(11):2351. doi: 10.3390/microorganisms9112351. PMID: 34835476 [Free PMC article](#). Review.
- 25 **Viral Hepatitis and Hepatocellular Carcinoma: State of the Art.**  
Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G.  
Pathogens. 2021 Oct 22;10(11):1366. doi: 10.3390/pathogens10111366.  
PMID: 34832522 [Free PMC article](#). Review.
- 26 **Role of autophagy in gastric carcinogenesis.**  
Papaefthymiou A, Christodoulidis G, Koffas A, Doulberis M, Polyzos SA, Manolakis A, Potamianos S, Kapsoritakis A, Kountouras J. World J Gastrointest Oncol. 2021 Oct 15;13(10):1244-1262. doi: 10.4251/wjgo.v13.i10.1244. PMID: 34721765 [Free PMC article](#). Review.
- 27 **Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease.**  
Papaefthymiou A, Doulberis M, Karafyllidou K, Chatzimichael E, Deretzi G, Exadaktylos AK, Sampsonas F, Gelasakis A, Papamichos SI, Kotronis G, Gialamprinou D, Vardaka E, Polyzos SA, Kountouras J.  
Minerva Endocrinol (Torino). 2021 Oct 20. doi: 10.23736/S2724-6507.21.03564-8. Online ahead of print. PMID: 34669319
- 28 **Impact of Helicobacter pylori-related Microbial Dysbiosis in the Pathogenesis of Metabolic Syndrome and Gastrointestinal Dysmotility Disorders.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Vardaka E, Boziki M, Kyriakopoulos A, Sampsonas F, Agrotis G, Karafyllidou K, Doulberis M. J Neurogastroenterol Motil. 2021 Oct 30;27(4):653-654. doi: 10.5056/jnm21059. PMID: 34642287 [Free PMC article](#). No abstract available.
- 29 **Commentary: are blood and saliva sources of COVID-19 spread?**  
Papaefthymiou A, Doulberis M, Polyzos SA, Romiopoulou I, Berdeni A, Zavos C, Vardaka E, Tzitivridou M, Kountouras J.  
Eur Rev Med Pharmacol Sci. 2021 Aug;25(15):4872-4874. doi: 10.26355/eurrev\_202108\_26444.  
PMID: 34355359 [Free article](#). No abstract available.
- 30 **Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients.**  
Doulberis M, Pierre NT, Manzini G, Papaefthymiou A, Kountouras J, Klukowska-Rötzler J, Polyzos SA, Srivastava S, Exadaktylos AK, Knuchel J, Kuntzen T, Srivastava DS.  
Microorganisms. 2021 Jun 23;9(7):1361. doi: 10.3390/microorganisms9071361. PMID: 34201748  
[Free PMC article](#).
- 31 **Prevalence and significance of mediastinal lymphadenopathy in patients with Severe Acute Respiratory Syndrome Corona Virus-2 infection.**  
Sampsonas F, Lagadinou M, Karampitsakos T, Solomou E, Doulberis M, Marangos M, Tzouveleki A. Eur Rev Med Pharmacol Sci. 2021 May;25(9):3607-3609. doi: 10.26355/eurrev\_202105\_25843. PMID: 34002835 [Free article](#).  
Review.
- 32 **The impact of COVID-19 pandemic on gastrointestinal diseases: a single-center cross-sectional study in central Greece.**  
Papaefthymiou A, Koffas A, Kountouras J, Doulberis M, Kaltsa A, Tsiopoulos F, Christodoulidis G, Kapsoritakis A, Potamianos S. Ann Gastroenterol. 2021;34(3):323-330. doi: 10.20524/aog.2021.0600. Epub 2021 Feb 26.

PMID: 33948056 [Free PMC article](#).

- 33 **Helicobacter pylori infection and diabetes mellitus.**  
Polyzos SA, Papaefthymiou A, Doulberis M, Mavridoglou G, Kountouras J.  
Diabetes Metab Syndr. 2021 May-Jun;15(3):845-846. doi: 10.1016/j.dsx.2021.03.034. Epub 2021 Apr 16. PMID: 33873053 No abstract available.
- 34 **Does COVID-19 Vaccination Warrant the Classical Principle "ofelein i mi vlaptin"?**  
Doulberis M, Papaefthymiou A, Kotronis G, Gialamprinou D, Soteriades ES, Kyriakopoulos A, Chatzimichael E, Kafayllidou K, Liatsos C, Chatzistefanou I, Anagnostis P, Semenin V, Ntona S, Gkolia I, Papazoglou DD, Tsinonis N, Papamichos S, Kirbas H, Zikos P, Niafas D, Kountouras J. Medicina (Kaunas). 2021 Mar 9;57(3):253. doi: 10.3390/medicina57030253. PMID: 33803295 [Free PMC article](#). Review.
- 35 **Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders.**  
Boziki M, Polyzos SA, Papaefthymiou A, Doulberis M, Bakirtzis C, Sintila SA, Touloumtzi M, Grigoriadis N, Kountouras J. Metabolism. 2021 May;118:154736. doi: 10.1016/j.metabol.2021.154736. Epub 2021 Feb 24. PMID: 33636167 No abstract available.
- 36 **The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis.**  
Boziki M, Grigoriadis N, Papaefthymiou A, Doulberis M, Polyzos SA, Gavalas E, Deretzi G, Karafoulidou E, Kesidou E, Taloumtzis C, Theotokis P, Sofou E, Katsinelos P, Vardaka E, Fludaras I, Touloumtzi M, Koukoufiki A, Simeonidou C, Liatsos C, Kountouras J. Neurochem Int. 2021 Mar;144:104938. doi: 10.1016/j.neuint.2020.104938. Epub 2021 Jan 31. PMID: 33535070 Review.
- 37 **A potential impact of Helicobacter pylori-related sarcopenia on severity of portal hypertension.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Doulberis M.  
Liver Int. 2021 May;41(5):1168-1169. doi: 10.1111/liv.14777. Epub 2021 Jan 9. PMID: 33386663 No abstract available.
- 38 **Impact of Helicobacter pylori-related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction.**  
Kountouras J, Papaefthymiou A, Doulberis M, Polyzos SA, Zavos C, Kazakos E, Tzika SK, Vardaka E, Liatsos C, Katsinelos P. J Neurogastroenterol Motil. 2021 Jan 30;27(1):147-148. doi: 10.5056/jnm20244. PMID: 33380559 [Free PMC article](#). No abstract available.
- 39 **The Potential Role of Super Spread Events in SARS-COV-2 Pandemic; a Narrative Review.**  
Kyriakopoulos AM, Papaefthymiou A, Georgilas N, Doulberis M, Kountouras J.  
Arch Acad Emerg Med. 2020 Sep 21;8(1):e74. eCollection 2020. PMID: 33134970  
[Free PMC article](#). Review.
- 40 **Helicobacter pylori, Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?**  
Doulberis M, Papaefthymiou A, Polyzos SA, Kotronis G, Gialamprinou D, Tziritidou-Chatzopoulou M, Touloumtzi M, Kountouras J. Obes Surg. 2021 Apr;31(4):1839-1840. doi: 10.1007/s11695-020-05066-2. Epub 2020 Oct 27. PMID: 33111248 No abstract available.
- 41 **Post-colonoscopy appendicitis: Causality or coincidence?**  
Doulberis M, Knuchel J, Hartmann M, Rupp S, Kuntzen T.  
J Gastroenterol Hepatol. 2021 Feb;36(2):523. doi: 10.1111/jgh.15293. Epub 2020 Nov 3. PMID: 33037844 No abstract available.
- 42 **Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection.**  
Doulberis M, Papaefthymiou A, Srivastava DS, Exadaktylos AK, Katsinelos P, Kountouras J, Polyzos SA. Int J Clin Pract. 2021 Apr;75(4):e13737. doi: 10.1111/ijcp.13737. Epub 2020 Nov 21. PMID: 32991019 No abstract available.
- 43 **The role of endoscopic ultrasound elastography in differentiating focal liver lesions.**

- Papaefthymiou A, Doulberis M, Papadopoulos V, Tsiopoulos F, Kapsoritakis A, Potamianos S, Kountouras J. *Eur J Gastroenterol Hepatol.* 2020 Oct;32(10):1408. doi: 10.1097/MEG.0000000000001825. PMID: 32858665 No abstract available.
- 44 **Helicobacter pylori infection as a potential risk factor for multiple sclerosis.**  
Kountouras J, Papaefthymiou A, Gavalas E, Polyzos SA, Boziki M, Kyriakou P, Katsinelos P, Zavos C, Liatsos C, Tzivras D, Tziritidou-Chatzopoulou M, Dardiotis E, Deretzi G, Vardaka E, Doulberis M.  
*Med Hypotheses.* 2020 Oct;143:110135. doi: 10.1016/j.mehy.2020.110135. Epub 2020 Jul 26. PMID: 32795839
- 45 **Reconsidering the "protective" hypothesis of Helicobacter pylori infection in eosinophilic esophagitis.**  
Doulberis M, Kountouras J, Rogler G.  
*Ann N Y Acad Sci.* 2020 Dec;1481(1):59-71. doi: 10.1111/nyas.14449. Epub 2020 Aug 7. PMID: 32770542  
[Free article.](#) Review.
- 46 **Erratum to: Letter to the editor re: Li et al. (2020), 'The potential role of bacteria in pancreatic cancer: A systematic review'.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Zavos C, Doulberis M.  
*Carcinogenesis.* 2020 Oct 15;41(10):1460. doi: 10.1093/carcin/bgaa073. PMID: 32770238  
No abstract available.
- 47 **Trimebutine Maleate Monotherapy for Functional Dyspepsia: A Multicenter, Randomized, Double-Blind Placebo Controlled Prospective Trial.**  
Kountouras J, Gavalas E, Papaefthymiou A, Tsechelidis I, Polyzos SA, Bor S, Diculescu M, Jadallah K, Tadeusz M, Karakan T, Bochenek A, Rozciecha J, Dabrowski P, Sparchez Z, Sezgin O, Gülten M, Farsakh NA, Doulberis M.  
*Medicina (Kaunas).* 2020 Jul 8;56(7):339. doi: 10.3390/medicina56070339. PMID: 32650518  
[Free PMC article.](#) Clinical Trial.
- 48 **Violence as the Most Frequent Cause of Oral and Maxillofacial Injuries among the Patients from Low- and Middle-Income Countries-A Retrospective Study at a Level I Trauma University Emergency Department in Switzerland.**  
Loutroukis T, Loutrouki E, Klukowska-Rötzel J, Koba S, Schlittler F, Schaller B, Exadaktylos AK, Doulberis M, Srivastava DS, Papoutsis S, Burkhard JPM. *Int J Environ Res Public Health.* 2020 Jul 7;17(13):4906. doi: 10.3390/ijerph17134906. PMID: 32646020 [Free PMC article.](#)
- 49 **Association between Active Helicobacter pylori Infection and Glaucoma: A Systematic Review and Meta-Analysis.**  
Doulberis M, Papaefthymiou A, Polyzos SA, Bargiotas P, Liatsos C, Srivastava DS, Zavos C, Katsinelos P, Kountouras J.  
*Microorganisms.* 2020 Jun 13;8(6):894. doi: 10.3390/microorganisms8060894.  
PMID: 32545826 [Free PMC article.](#) Review.
- 50 **Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited.**  
Polyzos SA, Papaefthymiou A, Doulberis M, Katsinelos P, Kountouras J.  
*J Gastrointest Liver Dis.* 2020 Jun 4;29(2):270-271. doi: 10.15403/jgld-1667.  
PMID: 32530998 [Free article.](#) No abstract available.
- 51 **Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.**  
Papaefthymiou A, Doulberis M, Polyzos SA, Katsinelos P, Kountouras J.  
*Aliment Pharmacol Ther.* 2020 Jun;51(11):1215-1216. doi: 10.1111/apt.15747.  
PMID: 32424925 No abstract available.
- 52 **Response to letter to the editor of Carcinogenesis by Li et al., 2020.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Zavos C, Doulberis M.  
*Carcinogenesis.* 2020 Jun 17;41(4):539-540. doi: 10.1093/carcin/bgaa042.  
PMID: 32396599 [Free article.](#) No abstract available.
- 53 **National consensus on Helicobacter pylori infection: the next-day challenge.**  
Papaefthymiou A, Doulberis M, Polyzos SA, Kountouras J.  
*Ann Gastroenterol.* 2020 May-Jun;33(3):324-325. doi: 10.20524/aog.2020.0469. Epub 2020 Mar 27.  
PMID: 32382241 [Free PMC article.](#) No abstract available.

- 54 **Correlation of registered drug packs in Greece with Maastricht V/Florence and Hellenic *Helicobacter pylori* infection treatment consensuses: A poor or a proper match?**  
Liatso C, Papaefthymiou A, Kyriakos N, Giakoumis M, Galanopoulos M, Petridou E, Doulberis M, Kountouras J. *Basic Clin Pharmacol Toxicol*. 2020 Jul;127(1):6-7. doi: 10.1111/bcpt.13416. Epub 2020 Apr 28. PMID: 32346986 [Free article](#). No abstract available.
- 55 **Impact of *Helicobacter pylori*-linked metabolic syndrome on non-alcoholic fatty liver disease and its connected atrial fibrillation risk.**  
Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA. *Liver Int*. 2020 Aug;40(8):2036-2037. doi: 10.1111/liv.14488. Epub 2020 Jun 7. PMID: 32333822  
No abstract available.
- 56 **Active *Helicobacter pylori* Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients.**  
Doulberis M, Srivastava S, Polyzos SA, Kountouras J, Papaefthymiou A, Klukowska-Rötzler J, Blank A, Exadaktylos AK, Srivastava DS. *J Clin Med*. 2020 Mar 30;9(4):933. doi: 10.3390/jcm9040933. PMID: 32235601 [Free PMC article](#).
- 57 **Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against *Helicobacter pylori* Infection in Greece: Do National Health Policy-Makers Need to Care?**  
Liatso C, Papaefthymiou A, Kyriakos N, Giakoumis M, Kountouras J, Galanopoulos M, Apostolopoulos P, Georgopoulos SD, Mavrogiannis C, Exadaktylos AK, Srivastava DS, Rokkas T, Doulberis M. *Medicina (Kaunas)*. 2020 Mar 18;56(3):133. doi: 10.3390/medicina56030133. PMID: 32197498  
[Free PMC article](#).
- 58 **Alzheimer's disease and gastrointestinal microbiota; impact of *Helicobacter pylori* infection involvement.**  
Doulberis M, Kotronis G, Glamprinou D, Polyzos SA, Papaefthymiou A, Katsinelos P, Kountouras J. *Int J Neurosci*. 2021 Mar;131(3):289-301. doi: 10.1080/00207454.2020.1738432. Epub 2020 Mar 13. PMID: 32125206 [Free article](#).
- 59 **Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents.**  
Doulberis M, Polyzos SA, Papaefthymiou A, Katsinelos P, Kiosses C, Kountouras J. *Expert Opin Pharmacother*. 2020 Feb;21(3):247-251. doi: 10.1080/14656566.2019.1702967. Epub 2020 Jan 1. PMID: 31893958 [Free article](#). No abstract available.
- 60 **Letter: *Helicobacter pylori* in proton pump inhibitor-associated biliary disease.**  
Papaefthymiou A, Doulberis M, Polyzos SA, Katsinelos P, Liatso C, Koffas A, Kazakos E, Deretzi G, Srivastava DS, Kountouras J. *Aliment Pharmacol Ther*. 2020 Jan;51(2):313-314. doi: 10.1111/apt.15608. PMID: 31880012 [Free article](#). No abstract available.
- 61 **Potential Impact of *Helicobacter pylori* Infection on Reflux Disease Sequence: Illuminating the Gap.**  
Kountouras J, Papaefthymiou A, Polyzos SA, Liatso C, Zavos C, Vagdatli E, Tsikopoulos G, Vardaka E, Tziritidou M, Katsinelos P, Doulberis M. *J Clin Gastroenterol*. 2020 Feb;54(2):200-201. doi: 10.1097/MCG.0000000000001302. PMID: 31851102 [Free article](#). No abstract available.
- 62 **Vitamin D Deficiency and Unclear Abdominal Pain in Patients from Low- and Middle-Income Countries.**  
Doulberis M, Papaefthymiou A, Kountouras J, Polyzos SA, Srivastava S, Klokowska-Rötzler J, Perrig M, Papoutsis S, Exadaktylos AK, Srivastava DS. *Int J Environ Res Public Health*. 2019 Nov 20;16(23):4607. doi: 10.3390/ijerph16234607. PMID: 31757059 [Free PMC article](#).
- 63 **Rodent models of obesity.**  
Doulberis M, Papaefthymiou A, Polyzos SA, Katsinelos P, Grigoriadis N, Srivastava DS, Kountouras J. *Minerva Endocrinol*. 2020 Sep;45(3):243-263. doi: 10.23736/S0391-1977.19.03058-X. Epub 2019 Nov 13. PMID: 31738033 [Free article](#). Review.
- 64 **The impact of selective serotonin receptor inhibitors on post-endoscopic sphincterotomy bleeding, alone or with concurrent aspirin or nonsteroidal anti-inflammatory drugs.**  
Katsinelos P, Lazaraki G, Anastasiadis S, Chatzimavroudis G, Katsinelos T, Terzoudis S, Gatopoulou A, Doulberis M, Papaefthymiou A, Kountouras J. *Ann Gastroenterol*. 2019 Nov-Dec;32(6):614-619. doi: 10.20524/aog.2019.0425. Epub 2019 Oct 8.

PMID: 31700239 [Free PMC article](#).

- 65 **Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.**  
Papaefthymiou A, Liatsos C, Georgopoulos SD, Apostolopoulos P, Doulberis M, Kyriakos N, Giakoumis M, Papadomichelakis M, Galanopoulos M, Katsinelos P, Rokkas T, Kountouras J.  
*Helicobacter*. 2020 Feb;25(1):e12666. doi: 10.1111/hel.12666. Epub 2019 Nov 6. PMID: 31692137  
[Free article](#).
- 66 **Impact of nitric oxide's bidirectional role on glaucoma: focus on Helicobacter pylori-related nitrosative stress.**  
Papaefthymiou A, Doulberis M, Katsinelos P, Liatsos C, Polyzos SA, Kotronis G, Papanikolaou K, Kountouras J. *Ann N Y Acad Sci*.  
2020 Apr;1465(1):10-28. doi: 10.1111/nyas.14253. Epub 2019 Oct 23. PMID: 31642532 [Free article](#). Review.
- 67 **Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis.**  
Boziki M, Grigoriadis N, Doulberis M, Papaefthymiou A, Polyzos SA, Kountouras J.  
*Dig Liver Dis*. 2020 Jan;52(1):121-123. doi: 10.1016/j.dld.2019.09.001. Epub 2019 Oct 17. PMID: 31629704  
[Free article](#). No abstract available.
- 68 **Influence of Helicobacter pylori-connected metabolic syndrome on non-alcoholic fatty liver disease and its related colorectal neoplasm high risk.**  
Kountouras J, Papaefthymiou A, Doulberis M, Polyzos SA.  
*Liver Int*. 2020 Feb;40(2):475-476. doi: 10.1111/liv.14264. Epub 2019 Oct 7. PMID: 31566879  
[Free article](#). No abstract available.
- 69 **Molecular Links Between Alzheimer's Disease and Gastrointestinal Microbiota: Emphasis on Helicobacter pylori Infection Involvement.**  
Katsinelos T, Doulberis M, Polyzos SA, Papaefthymiou A, Katsinelos P, Kountouras J.  
*Curr Mol Med*. 2019;20(1):3-12. doi: 10.2174/1566524019666190917125917. PMID: 31530263  
[Free article](#). Review.
- 70 **Current Aspects on Differentiating Relapses from Over-Infections in Symptomatic Inflammatory Bowel Diseases.**  
Liatsos C, Papaefthymiou A, Tzouvala M, Doulberis M, Petridou E, Kountouras J.  
*Dig Dis Sci*. 2019 Sep;64(9):2686-2687. doi: 10.1007/s10620-019-05755-8. Epub 2019 Jul 25.  
PMID: 31346953 [Free article](#). No abstract available.
- 71 **A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection.**  
Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA, Vardaka E, Tzivras D, Dardiotis E, Deretzi G, Giartza-Taxidou E, Grigoriadis S, Katsinelos P. *Ann N Y Acad Sci*. 2019 Sep;1452(1):12-17. doi: 10.1111/nyas.14168. Epub 2019 Jul 16. PMID: 31310338
- 72 **The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders.**  
Kountouras J, Gavalas E, Doulberis M, Polyzos SA, Papaefthymiou A, Touloumtzi M, Vardaka E, Kountouras K, Papanikolopoulou K, Katsinelos P. *J Neurogastroenterol Motil*. 2019 Jul 1;25(3):473-474. doi: 10.5056/jnm19033. PMID: 31177649 [Free PMC article](#). No abstract available.
- 73 **The relationship between Helicobacter pylori-related microbiota dysbiosis and gastrointestinal tract pathologies.**  
Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA, Touloumtzi M, Vardaka E, Kapetanakis N, Liatsos C, Gavalas E, Anastasiadis S, Tzivras D, Katsinelos P.  
*Scand J Gastroenterol*. 2019 Jun;54(6):806-807. doi: 10.1080/00365521.2019.1619826. Epub 2019 May 25.  
PMID: 31131650 [Free article](#). No abstract available.
- 74 **Impact of occupational stress on irritable bowel syndrome pathophysiology and potential management in active duty noncombat Greek military personnel: a multicenter prospective survey.**  
Papaefthymiou A, Doulberis M, Kountouras J, Kolokytha C, Galanopoulos M, Liatsos C, Kyriakos N, Giakoumis M, Papadomichelakis M, Polyzos SA, Kotronis G, Katsinelos P.  
*Eur J Gastroenterol Hepatol*. 2019 Aug;31(8):954-963. doi: 10.1097/MEG.0000000000001439. PMID: 31107738 [Free article](#).

- 75 **Gastroesophageal reflux disease, irritable bowel syndrome and functional dyspepsia as overlapping conditions: focus on effect of trimebutine.**  
Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA.  
Ann Gastroenterol. 2019 May-Jun;32(3):318. doi: 10.20524/aog.2019.0366. Epub 2019 Feb 18. PMID: 31040633  
[Free PMC article](#). No abstract available.
- 76 **Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection.**  
Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA, Touloumtzi M, Elisabeth V, Kapetanakis N, Liatsos C, Gavalas E, Katsinelos P. Cell Mol Life Sci. 2019 Jul;76(13):2487-2488. doi: 10.1007/s00018-019-03106-4. Epub 2019 Apr 20.  
PMID: 31006036 [Free article](#). No abstract available.
- 77 **Microbes and Alzheimer' disease: lessons from H. pylori and GUT microbiota.**  
Doulberis M, Papaefthymiou A, Polyzos SA, Boziki M, Deretzi G, Giartza-Taxidou E, Vardaka E, Grigoriadis N, Katsinelos T, Touloumtzi M, Papanikopoulou K, Anastasiadou K, Georgopoulos S, Dardiotis E, Anastasiadis S, Katsinelos P, Kountouras J.  
Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):1845-1846. doi: 10.26355/eurrev\_201903\_17218. PMID: 30915725  
[Free article](#). No abstract available.
- 78 **Metabolic syndrome components including high abdominal obesity and sarcopenia in patients with inflammatory bowel disease.**  
Kountouras J, Doulberis M, Polyzos SA, Katsinelos P.  
Ann Gastroenterol. 2019 Mar-Apr;32(2):214. doi: 10.20524/aog.2019.0349. Epub 2019 Jan 15.  
PMID: 30872916 [Free PMC article](#). No abstract available.
- 79 **Impact of Helicobacter pylori and/or Helicobacter pylori-related metabolic syndrome on incidence of all-cause and Alzheimer's dementia.**  
Kountouras J, Doulberis M, Polyzos SA, Katsinelos T, Vardaka E, Kountouras C, Arapoglou S, Exadaktylos AK, Deretzi G, Tsolaki M, Boziki M, Katsinelos P.  
Alzheimers Dement. 2019 May;15(5):723-725. doi: 10.1016/j.jalz.2019.01.008. Epub 2019 Mar 11.  
PMID: 30872115 No abstract available.
- 80 **Comments to the Editor concerning the paper entitled "The microbiome and ophthalmic disease" by Baim et al.**  
Doulberis M, Polyzos SA, Papaefthymiou A, Katsinelos P, Kountouras J.  
Exp Biol Med (Maywood). 2019 Apr;244(6):430-432. doi: 10.1177/1535370218824340. Epub 2019 Jan 17.  
PMID: 30654636 [Free PMC article](#). No abstract available.
- 81 **Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease.**  
Polyzos SA, Kountouras J, Mavrouli M, Katsinelos P, Doulberis M, Gavana E, Duntas L.  
Exp Clin Endocrinol Diabetes. 2019 Oct;127(9):598-602. doi: 10.1055/a-0811-9136. Epub 2019 Jan 9.  
PMID: 30625508 Clinical Trial.
- 82 **Acute Liver Failure: From Textbook to Emergency Room and Intensive Care Unit With Concomitant Established and Modern Novel Therapies.**  
Doulberis M, Kotronis G, Gialamprinou D, Özgüler O, Exadaktylos AK, Oikonomou V, Katsinelos P, Romiopoulou I, Polyzos SA, Tzivras D, Deretzi G, Dardiotis E, Kountouras J.  
J Clin Gastroenterol. 2019 Feb;53(2):89-101. doi: 10.1097/MCG.0000000000001162.  
PMID: 30575637 [Free article](#). Review.
- 83 **Hookworms in Emergency Department: The " Vampire " Within.**  
Doulberis M, Papaefthymiou A, Kountouras J, Polyzos SA, Srivastava DS, Perrig M, Katsinelos P, Özgüler O, Kotronis G, Gialamprinou D, Papamichos S, Ingold J, Xanthis A, Exadaktylos AK.  
J Acute Med. 2018 Dec 1;8(4):135-148. doi: 10.6705/j.jacme.201812\_8(4).0001. PMID: 32995216 [Free PMC article](#). Review.
- 84 **Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.**  
Polyzos SA, Kountouras J, Anastasilakis AD, Makras P, Hawa G, Sonnleitner L, Missbichler A, Doulberis M, Katsinelos P, Terpos E.  
Hormones (Athens). 2018 Dec;17(4):573-579. doi: 10.1007/s42000-018-0083-8. Epub 2018 Nov 22.  
PMID: 30467685 Clinical Trial.



- 85 **Potential Impact of Active *Helicobacter pylori* Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality.**  
Kountouras J, Doulberis M, Polyzos SA, Papaefthymiou A, Kapetanakis N, Arapoglou S, Venizelos I, Vardaka E, Kotronis G, Anastasiadis S, Katsinelos P. *Isr Med Assoc J*. 2018 Nov;20(11):725-726.  
PMID: 30430809 [Free article](#). No abstract available.
- 86 **Impact of *Helicobacter pylori* and/or *Helicobacter pylori*-related metabolic syndrome on gastroesophageal reflux disease- Barrett's esophagus- esophageal adenocarcinoma sequence.**  
Doulberis M, Kountouras J, Polyzos SA, Tzivras D, Vardaka E, Kountouras C, Tzilves D, Kotronis G, Boutsikou E, Gialamprinou D, Exadaktylos A, Katsinelos P. *Helicobacter*. 2018 Dec;23(6):e12534. doi: 10.1111/hel.12534. Epub 2018 Sep 12. PMID: 30209842  
No abstract available.
- 87 ***Helicobacter pylori* Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence.**  
Kountouras J, Doulberis M, Polyzos SA, Zeglinas C, Vardaka E, Kountouras C, Tzivras D, Dardiotis E, Exadaktylos A, Katsinelos P. *Am J Gastroenterol*. 2018 Nov;113(11):1723-1724. doi: 10.1038/s41395-018-0214-5. Epub 2018 Sep 3.  
PMID: 30177783 No abstract available.
- 88 **A RARE CASE OF CROHN DISEASE COMPLICATED WITH STEROID MONOTHERAPY-RELATED RETROPHARYNGEAL ABSCESS AND INITIALLY MISINTERPRETED PYODERMA GANGRENOSUM DEVELOPMENT.**  
Doulberis M, Dähn J, Kountouras J, Maier V, Helbling A, Dubach P. *Gastroenterol Nurs*. 2018 Jul/Aug;41(4):347-351. doi: 10.1097/SGA.0000000000000401.  
PMID: 30063691 No abstract available.
- 89 **Potential impact of *Helicobacter pylori*-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis.**  
Kountouras J, Polyzos SA, Doulberis M, Zeglinas C, Artemaki F, Vardaka E, Deretzi G, Giartza-Taxidou E, Tzivras D, Vlachaki E, Kazakos E, Katsinelos P, Mantzoros CS. *Metabolism*. 2018 Oct;87:18-24. doi: 10.1016/j.metabol.2018.06.008. Epub 2018 Jun 21. PMID: 29936174  
Review.
- 90 **Comment on "Therapeutic Application of an Extract of *Helicobacter pylori* Ameliorates the Development of Allergic Airway Disease".**  
Kountouras J, Polyzos SA, Doulberis M, Stergiopoulos C, Katsinelos P. *J Immunol*. 2018 May 1;200(9):3027. doi: 10.4049/jimmunol.1800155. PMID: 29685946 No abstract available.
- 91 **Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?**  
Polyzos SA, Kountouras J, Anastasiadis S, Doulberis M, Katsinelos P. *Hepatology*. 2018 Jul;68(1):389. doi: 10.1002/hep.29897.  
PMID: 29601090 No abstract available.
- 92 **Potential Impact of *Helicobacter Pylori* on Hepatic Encephalopathy Pathophysiology.**  
Kountouras J, Polyzos SA, Katsinelos P, Anastasiadis S, Tzivras D, Doulberis M, Venizelos I, Vardaka E, Kountouras C, Deretzi G. *Dig Dis Sci*. 2018 Apr;63(4):1087-1088. doi: 10.1007/s10620-018-4911-0. Epub 2018 Feb 21. PMID: 29468372 No abstract available.
- 93 ***Helicobacter pylori* infection and esophageal adenocarcinoma: a review and a personal view.**  
Polyzos SA, Zeglinas C, Artemaki F, Doulberis M, Kazakos E, Katsinelos P, Kountouras J. *Ann Gastroenterol*. 2018 Jan-Feb;31(1):8-13. doi: 10.20524/aog.2017.0213. Epub 2017 Nov 16.  
PMID: 29333062 [Free PMC article](#). Review.
- 94 **The Emerging Role of *Helicobacter Pylori*-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration.**  
Kountouras J, Boziki M, Polyzos SA, Katsinelos P, Gavalas E, Zeglinas C, Tzivras D, Romiopoulou I, Giorgakis N, Anastasiadou K, Vardaka E, Kountouras C, Kazakos E, Giartza-Taxidou E, Deretzi G, Dardiotis E, Kotronis G, Doulberis M. *Curr Mol Med*. 2017;17(6):389-404. doi: 10.2174/1566524018666171219094837.  
PMID: 29256351 Review.
- 95 **A potential impact of *Helicobacter pylori*-related galectin-3 in neurodegeneration.**

- Boziki M, Polyzos SA, Deretzi G, Kazakos E, Katsinelos P, Doulberis M, Kotronis G, Giartza-Taxidou E, Laskaridis L, Tzivras D, Vardaka E, Kountouras C, Grigoriadis N, Thomann R, Kountouras J.  
*Neurochem Int.* 2018 Feb;113:137-151. doi: 10.1016/j.neuint.2017.12.003. Epub 2017 Dec 13.  
PMID: 29246761 Review.
- 96 **Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far?**  
Doulberis M, Kotronis G, Thomann R, Polyzos SA, Boziki M, Gialamprinou D, Deretzi G, Katsinelos P, Kountouras J. *Helicobacter.* 2018 Feb;23(1). doi: 10.1111/hel.12454. Epub 2017 Nov 27.  
PMID: 29181894 Review.
- 97 **Obesity and the nervous system: more questions.**  
Kountouras J, Polyzos SA, Katsinelos P, Kotronis G, Doulberis M.  
*Lancet Neurol.* 2017 Oct;16(10):772-773. doi: 10.1016/S1474-4422(17)30291-0. Epub 2017 Sep 12.  
PMID: 28920879 No abstract available.
- 98 **Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease.**  
Kountouras J, Polyzos SA, Katsinelos P, Doulberis M, Zavos C, Kazakos E, Boziki M, Tzivras D, Kotronis G. *Aliment Pharmacol Ther.* 2017 Sep;46(6):637-638. doi: 10.1111/apt.14222.  
PMID: 28805327 No abstract available.
- 99 **Is there an Association between Migraine and Gastrointestinal Disorders?**  
Doulberis M, Saleh C, Beyenburg S.  
*J Clin Neurol.* 2017 Jul;13(3):215-226. doi: 10.3988/jcn.2017.13.3.215.  
PMID: 28748672 [Free PMC article](#). Review.
- 100 **Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.**  
Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P.  
*Metabolism.* 2017 Jun;71:182-197. doi: 10.1016/j.metabol.2017.03.013. Epub 2017 Mar 31.  
PMID: 28521872 Review.
- 101 **Update on ischemic colitis: from etiopathology to treatment including patients of intensive care unit.**  
Doulberis M, Panagopoulos P, Scherz S, Dellaporta E, Kouklakis G.  
*Scand J Gastroenterol.* 2016 Aug;51(8):893-902. doi: 10.3109/00365521.2016.1162325. Epub 2016 May 6.  
PMID: 27152750 Review.
- 102 **PEPTIC STRICTURE MIMICKING ESOPHAGEAL CANCER: A CASE REPORT.**  
Vradelis S, Doulberis M, Dellaporta E, Babali A, Panagopoulos P, Efraimidou E, Kouklakis G.  
*Gastroenterol Nurs.* 2015 Sep-Oct;38(5):384-6. doi: 10.1097/SGA.000000000000164.  
PMID: 26422273 No abstract available.
- 103 **Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer.**  
Doulberis M, Angelopoulou K, Kaldrymidou E, Tsingotjidou A, Abas Z, Erdman SE, Poutahidis T. *Carcinogenesis.* 2015 Feb;36(2):280-90. doi: 10.1093/carcin/bgu325. Epub 2014 Dec 30. PMID: 25550315 [Free PMC article](#).
- 104 **Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice.**  
Poutahidis T, Cappelle K, Levkovich T, Lee CW, Doulberis M, Ge Z, Fox JG, Horwitz BH, Erdman SE. *PLoS One.* 2013 Aug 26;8(8):e73933. doi: 10.1371/journal.pone.0073933. eCollection 2013. PMID: 23991210 [Free PMC article](#).
- 105 **Establishment of an animal model for Waldenström's macroglobulinemia.**  
Tsingotjidou AS, Emmanouilides CE, Siotou E, Poutahidis T, Xagorari A, Loukopoulos P, Sotiropoulos D, Bekiari C, Doulberis M, Givissis P, Fassas A, Anagnostopoulos A.  
*Exp Hematol.* 2009 Apr;37(4):469-76. doi: 10.1016/j.exphem.2008.12.007.  
PMID: 19302921 [Free article](#).
- 106 **Mycotic encephalitis and nephritis in a dog due to infection with Cladosporium cladosporioides.**

Poutahidis T, Angelopoulou K, Karamanavi E, Polizopoulou ZS, Doulberis M, Latsari M, Kaldrymidou E. *J Comp Pathol.* 2009 Jan;140(1):59-63. doi: 10.1016/j.jcpa.2008.09.002. Epub 2008 Dec 7. PMID: 19064269

107 [Primary gastric choriocarcinoma in a dog.](#)

Poutahidis T, Doulberis M, Karamanavi E, Angelopoulou K, Koutinas CK, Papazoglou LG. *J Comp Pathol.* 2008 Aug-Oct;139(2-3):146-50. doi: 10.1016/j.jcpa.2008.06.003. Epub 2008 Aug 8. PMID: 18691724

« First < Prev Page 1 of 1 Next > Last »

FOLLOW NCBI



Connect with NLM

National Library of  
Medicine  
8600 Rockville Pike  
Bethesda, MD 20894

Web Policies  
FOIA  
HHS Vulnerability  
Disclosure

Help  
Accessibility  
Careers

NLM NIH HHS USA.gov